Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Jennifer H. Foster et al.|Neuro-Oncology|2022Cited by 136
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61
HGG-32. PNOC008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA)Andrea Franson, Sabine Mueller, Lindsay Kilburn et al.|Neuro-Oncology|2024Cited by 2
PNOC014: Phase I Study of Tovorafenib for Children With Relapsed/Recurrent Low-Grade Gliomas and Other Mitogen Activated Protein Kinase Pathway–Activated TumorsKaren Wright, Sabine Mueller, Cassie Kline et al.|JCO oncology advances.|2026Cited by 0